The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.
To own DEXUS today, you need to believe its shift toward higher quality, diversified real assets and capital recycling can offset pressure in office and funds management earnings. The sharp move to a A$122.05 million full year loss and reduced revenue puts the near term focus squarely on whether disposals and development projects can support distributable income, while amplifying the key risk around elevated funding needs and the resilience of fee based revenues.
The most relevant recent announcement is the sale of 480 Queen Street in Brisbane for around A$700 million, as part of DEXUS’s broader office selldown. In light of the latest loss, this transaction looks increasingly central to the story: it crystallises capital, reduces CBD office exposure and potentially supports the balance sheet at a time when gearing, interest costs and development funding requirements sit at the heart of the risk and catalyst debate.
Yet behind the headlines, investors should also be aware of how ongoing redemption pressures and asset sales could interact with a weaker earnings base...
Read the full narrative on DEXUS (it's free!)
DEXUS' narrative projects A$952.7 million revenue and A$715.3 million earnings by 2029.
Uncover how DEXUS' forecasts yield a A$7.35 fair value, a 27% upside to its current price.
Before this result, the most optimistic analysts were assuming DEXUS could reach about A$1.1 billion in earnings on roughly A$1.2 billion of revenue, which sits in sharp contrast to the latest A$122.05 million loss and raises questions about how quickly the funds management and development pipelines can realistically offset ongoing office and financing risks.
Explore 3 other fair value estimates on DEXUS - why the stock might be worth just A$6.77!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com